Photo from wikipedia
Atrial fibrillation (AF) is common in patients with diabetes and heart failure (HF) and increases the future risk of adverse cardiovascular (CV) outcomes. This analysis from the EMPA‐REG OUTCOME trial… Click to show full abstract
Atrial fibrillation (AF) is common in patients with diabetes and heart failure (HF) and increases the future risk of adverse cardiovascular (CV) outcomes. This analysis from the EMPA‐REG OUTCOME trial explores CV and renal outcomes in patients with vs. without AF at baseline and assesses the benefits of empagliflozin.
Keywords:
atrial fibrillation;
heart;
heart failure;
empa reg;
reg outcome
Journal Title: European Journal of Heart Failure
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: European Journal of Heart Failure
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!